fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      47   |   48   |   49   |   50   |   51   |   52   |   53   |   54   |   55   |   56   |   57      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2006-09-19 I Launch Genfit (France)   GFT505 (PPAR nuclear receptor activator) mixed dyslipidaemia, type 2 diabetes, atherosclerosis   See details
2006-09-19 II Launch Addex Pharmaceuticals (Switzerland)   ADX10059 (modulates the type 5 metabotropic glutamate receptor) gastro-oesophageal reflux Germany, United Kingdom See details
2006-09-19 II Launch pSivida (Australia)   mifepristone (RU486 ? steroid receptor antagonist) Elevated intraocular pressure   See details
2006-09-19 II Launch Addex Pharmaceuticals (Switzerland)   ADX10061 (selective D1 dopamine receptor antagonist) smoking USA See details
2006-09-18 II Launch Astion Pharma (Denmark)   ASF-1096 discoid lupus erythaematosus six centres in Denmark See details
2006-09-18 III Launch Zymogenetics (USA)   recombinant human thrombin control of haemorrhage during surgery 34 sites in the USA ? 411 patients See details
2006-09-12 I Launch Karo Bio (Sweden) Merck&Co (USA) oestrogen receptor     See details
2006-09-12 III Result Serono (Switzerland) BioMarin (USA)   Phenoptin® (sapropterin) phenylketonuria   See details
2006-09-12 III Launch Arena Pharmaceuticals (USA)   lorcaserine obesity USA See details
2006-08-30 II Launch Addex Pharmaceuticals (Switzerland)   ADX10059 Acute migraine treatment Germany, United Kingdom See details
2006-08-18 II Launch NeuroSearch (Denmark)   tesofensine obesity   See details
2006-08-16 I Launch Alantos Pharmaceuticals (USA/Germany)   ALS 2-046 (dipeptidylpeptidase IV (DDP-IV) inhibitor) type 2 diabetes USA See details
2006-08-07 I-II Launch Wilex (Germany)   WX-671 (Mesupron®- oral small molecule serine protease inhibitor) This product is an orally available pro-drug of WX-UK1, small molecule serine protease inhibitor that targets the urokinase Plasminogen Activator (uPA) system. head and neck cancer   See details
2006-08-03 I Launch Immutep (France)   Immufact®IMP321 metastatic breast carcinoma   See details
2006-07-26 I Result Revotar Biopharmaceuticals (Germany)   bimosiamose (selectin cell adhesion molecule antagonist) chronic inflammatory diseases   See details
[<<]      «      47   |   48   |   49   |   50   |   51   |   52   |   53   |   54   |   55   |   56   |   57      »      [57]